Shots:
- The US FDA has granted RMAT Designation to KB707 for the treatment of advanced or metastatic NSCLC
- Designation was supported by the ongoing P-I/II (KYANITE-1) trial assessing KB707 (administered via nebulization) across 7 cohorts: Arms 1-4 as monotx., Arm 5 with Keytruda, Arm 6 with Keytruda & CT & Arm 7 with CT alone
- Trial showed consistent & significant antitumor activity, incl. durable responses & meaningful tumor reductions, in pts with heavily pre-treated advanced NSCLC
Ref: Krystal Biotech | Image: Krystal Biotech | Press Release
Related News: Krystal Biotech’s Vyjuvek (Beremagene Geperpavec-svdt) Receives the EC’s Approval for Dystrophic Epidermolysis Bullosa (DEB)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
